Bibliography
- MUNOZ N: Human papillomavirus and cancer: the epidemiological evidence. j. Viral. (2000) 19:1–5.
- ZUR HAUSEN H: Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. I Natl. Cancer Inst. (2000) 92:690–698.
- STUBENRAUCH F, LAIMINS LA: Humanpapillomavirus life cycle: active and latent phases. Sernin. Cancer Biol. (1999) 9:379–386.
- BREITBURD F, COURSAGET P: Humanpapillomavirus vaccines. Sernin. Cancer Biol. (1999) 9:431–444.
- DA SILVA DM, EIBEN GL, FAUSCH SC, et al: Cervical cancer vaccines: emerging concepts and developments. I Cell Physiol. (2001) 186:169–182.
- LING M, KANAYAMA M, RODEN R, WU TC: Preventive and therapeutic vaccines for human papillomavirus-associated cervical cancers. J. Blamed. Sci. (2000) 7:341–356.
- ROBBINS JB, SCHNEERSON R, SZU SC: Hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. J. Infect. Dis. (1995) 171:1387–1398.
- SCHILLER JT, LOWY DR: Papillomavirus-like particles and HPV vaccine development. Semin. Cancer Biol. (1996) 7:373–382.
- KIRNBAUER R, BOOY F, CHENG N, LOWY DR, SCHILLER JT: Papillomavirus Li major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc. Natl. Acad . Li. USA (1992) 89:12180–12184.
- •First report of papffiomavirus Li VLPs and their ability to induce high titres of neutralising antibodies.
- HAGENSEE ME, YAEGASHI N, GALLOWAY DA: Self-assembly of human papillomavirus Type 1 capsids by expression of the Li protein alone or by coexpression of the Li and L2 capsid proteins. 1. Viral. (1993) 67:315–322.
- ROSE RC, BONNEZ W REICHMAN RC, GARCEA RL: Expression of human papillomavirus Type 11 Li protein in insect cells: in vivo and in vitro assembly of viruslike particles. 1. Viral. (1993) 67:1936–1944.
- HOFMANN K, COOK J, JOYCE J et al: Sequence determination of Human Papillomavirus 6a and assembly of virus-like particles in Saccharomyces cerevisiae. Virology (1995) 209:506–518.
- NARDELLI-HAEFLIGER D, RODEN RBS, BENYACOUB J et al: Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella hphimurium elicit mucosal and systemic neutralising antibodies in mice. Inf. Immun. (1997) 65:3328–3336.
- CHEN XS, CASINI G, HARRISON SC, GARCEA RL: Papillomavirus capsid protein expression in Escherichia colt. Purification and assembly of HPV ii and HPV16 L1.1 Mai Biol. (2001) 307:173–182.
- TRUS BL, RODEN RBS, GREENSTONE et al.: Novel structural features of bovine papillomavirus capsid revealed by a three dimensional reconstruction to 9A resolution. Nature Struct. Biol. (1997) 4:413–420.
- KIRNBAUER R, TAUB J, GREENSTONE H et al.: Efficient self-assembly of human papillomavirus Type 16 Li and Li-L2 into virus-like particles. 1. Viral. (1993) 67:6929–6936.
- VOLPERS C, SCHIRMACHER P, STREECK RE, SAPP M: Assembly of the major and the minor capsid protein of human papillomavirus Type 33 into virus-like particles and tubular structures in insect cells. Virology (1994) 200:504–512.
- CHRISTENSEN ND, HOPFL R, DIANGELO et al.: Assembled baculovirus-expressed human papillomavirus Type 11 Li capsid protein virus-like particles are recognised by neutralising monoclonal antibodies and induce high titres of neutralising antibodies. 1 Gen. Viral . (1994) 75:2271–2276.
- MCCARTHY MP, WHITE WI, PALMER-HILL F, KOENIG S, SUZICH JA: Quantitative disassembly and reassembly of human papillomavirus type 11 virus-like particles in vitro. 1. Viral. (1998) 72:32–41.
- COOK JC, JOYCE JG, GEORGE HA et al.: Purification of virus-like particles of recombinant human papillomavirus type 11 major capsid protein Li from Saccharomyces cerevisiae. Protein Expr. Purif (1999) 17:477–484
- HARRO CD, PANG YY, RODEN RB et al.: Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 Li virus-like particle vaccine. 1. Nati Cancer Inst. (2001) 93:284–292.
- ••Only published clinical trial of a VLPvaccine against an oncogenic HPV type.
- ROSE RC, WHITE WI, LI M et al.: Human papillomavirus type 11 recombinant Li capsomeres induce virus-neutralising antibodies. 1 Viral. (1998) 72:6151–6154.
- CHRISTENSEN ND, KIRNBAUER R,SCHILLER JT et al.: Human papillomavirus types 6 and 11 have antigenically distinct strongly immunogenic conformationally dependent neutralising epitopes. Virology (1994) 205:329–335.
- RODEN RBS, GREENSTONE HL, KIRNBAUER R et al.: In vitro generation and type-specific neutralisation of a human papillomavirus Type 16 virion pseudotype. 1. Viral. (1996) 70:5875–5883.
- UNCKELL F, STREECK RE, SAPP M: Generation and neutralisation of pseudovirions of human papillomavirus Type 33.1 Viral. (1997) 71:2934–2939.
- LOWE RS, BROWN DR, BRYAN JT et al.: Human papillomavirus Type 11 (HPV11) neutralising antibodies in the serum and genital mucosal secretions of African green monkeys immunised with HPV-11 virus-like particles expressed in yeast. J. Infect. Dis. (1997) 176:1141–1145.
- WHITE WI, WILSON SD, BONNEZ W ROSE RC, KOENIG S, SUZICH JA: In vitro infection and type-restricted antibody-mediated neutralisation of authentic human papillomavirus Type 16.1 Viral. (1998) 72:959–964.
- BOSCH FX, MANOS MM, MUNOZ N etal.: Prevalence of human papillomavirus in cervical cancer: a worldwide prospective. 1. Nat. Cancer Inst. (1995) 87:796–802.
- WALBOOMERS JM, JACOBS MC, MAN 05 MM, BOSCH FX, KUMMER JA, SHAH KV: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. I Pathol. (1999) 189:12–19.
- BREITBURD F, KIRNBAUER R, HUBBERT NL et al.: Immunisation with virus-like particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. I Viral. (1995) 69:3959–3963.
- SUZICH JA, GHIM S, PALMER-HILL et al.: Systemic immunisation with papillomavirus Li protein completely prevents the development of viral mucosal papillomas. Proc. Natl. Acad. Li. USA (1995) 92:11553–11557.
- ••Impressive protection from high dose viruschallenge after low dose VLP vaccination in an oral mucosal model.
- KIRNBAUER R, CHANDRACHUD L, O'NEIL B et al.: Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunisation. Virology (1996) 219:37–44.
- BAMELLI C, RODEN R, POTTS A, SCHILLER J, DE GRANDE P, NARNELLI-HAEFLIGER D: Nasal immunisation of mice with human papillomavirus type 16 virus-like particles elicits neutralising antibodies in mucosal secretions. 1. Viral. (1998) 8220–8229.
- LIU XS, ABDUL-JABBAR I, QI YM, FRAZER IH, ZHOU J: Mucosal immunisation with papillomavirus virus-like particles elicits systemic and mucosal immunity in mice. Virology (1998) 252:39–45.
- DUPUY C, BUZONI-GATEL D, TOUZE A, BOUT D, COURSAGET P: Nasal immunisation of mice with human papillomavirus Type 16 (HPV-16) virus-like particles or with the HPV-16 Li gene elicits specific cytotoxic T lymphocytes in vaginal draining lymph nodes. j Viral. (1999) 73:9063–9071.
- ROSE RC, LANE C, WILSON S, SUZICH JA, RYBICKI E, WILLIAMSON AL: Oral vaccination of mice with human papillomavirus virus-like particles induces systemic virus-neutralising antibodies. Vaccine (1999) 17:2129–2135.
- EVANS TG, BONNEZ W, ROSE RC et al.: A Phase 1 study of a recombinant virus-like particle vaccine against human papillomavirus Type 11 in healthy adult volunteers. j Infect. Dis. (2001) 183:1485–1493.
- •Examination of antibody and T-cell responses to VLPs of a genital wart-associated virus.
- ZHANG LF, ZHOU J, CHEN S et al.: HPV 6b virus like particles are potent immunogens without adjuvant in man. Vaccine (2000) 18:1051–1058.
- •Only published report of a VLP vaccine trial in patients with an HPV disease.
- MCNEIL C: HPV vaccines for cervical cancer move toward clinic, encounter social issues. J Natl. Cancer Inst. (1997) 89:1664–1666.
- BOUVET JP, BELEC L, PIRES R, PILLOT J: Immunoglobulin G antibodies in human vaginal secretions after parenteral vaccination. Infect. bran= (1994) 62:3957–3961.
- VAN GINKEL FW, VANCOTT JL, KIYONO H, MCGHEE JR: Mucosal immunity to human papillomavirus in the female reproductive tract. Papillainavirus Reports (1997) 8:1–10.
- HERRERO R, HILDESHEIM A, BRATTI C et al.: Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. j Natl. Cancer Inst. (2000) 92:464–474.
- DE BRUIJN MLH, GREENSTONE HL, VERMEULEN H etal.: Li-specific protection from tumour challenge elicited by HPV16 virus-like particles. Virology (1998) 250:371–376.
- MULLER M, ZHOU J, REED TD et al.: Chimeric papillomavirus-like particles. Virology (1997) 234:93–111.
- •Initial report of the Li chimeric VLP technology.
- PENG S, FRAZER IH, FERNANDO GJ, ZHOU J: Papillomavirus virus-like particles can deliver defined CTL epitopes to the MHC class I pathway. Virology (1998) 240:147–157.
- GREENSTONE HL, NIELAND JD, DE VISSER KE et al.: Chimeric papillomavirus virus-like particles elicit antitumour immunity against the E7 oncoprotein in an HPV16 tumour model. Proc. Nati Acad. Sci. USA (1998) 95:1800–1805.
- ••Initial report of the L2 chimeric VLPtechnology.
- SCHAFER K, MULLER M, FAATH S et al.: Immune response to human papillomavirus 16 L1E7 chimeric virus-like particles: induction of cytotoxic T cells and specific tumour protection. Int. j Cancer (1999) 81:881–888.
- KIVIAT N, KOUTSKY LA, PAAVONEN J: Cervical neoplasia and other STD-related genital tract neoplasias. In: Sexually Transmitted Diseases. Holmes KK, Spalding Mardh P-A, Lemon SM, Piot P, Wasserheit JN (Eds.) (1998).
- BONTKES HJ, WALBOOMERS JM, MEIJER CJ, HELMERHORST TJ, STERN PL: Specific HLA class I down-regulation is an early event in cervical dysplasia associated with clinical progression. Lancet (1998) 351:187–188.
- BRADY CS, BARTHOLOMEW JS, BURT DJ et al.: Multiple mechanisms underlie HLA dysregulation in cervical cancer. Tissue Antigens (2000) 55:401–411.
- KOOPMAN LA, CORVER WE, VAN DER SLIK AR, GIPHART MJ, FLEUREN GJ: Multiple genetic alterations cause frequent and heterogeneous human histocompatibility leukocyte antigen class I loss in cervical cancer. j Exp. Med. (2000) 191:961–976.
- RAMSHAW IA, RAMSAY AJ: The prime-boost strategy: exciting prospects for improved vaccination. hninunal. Today (2000) 21:163–165.
- NIELAND JD, DA SILVA DM, VELDERS MP etal.: Chimeric papillomavirus virus-like particles induce a murine self- antigen-specific protective and therapeutic antitumour immune response. Cell Biachent (1999) 73:145–152.
- ••Chimeric VLP mediated tumourimmunotherapy against a tumour antigen peptide that is tolerating when administered as a free peptide.
- BACHMANN ME ZINKERNAGEL RIVI: Neutralising antiviral B cell responses. Ann. Rev Innnunal. (1997) 15:235–270.
- FEHR T, SKRASTINA D, PUMPENS P, ZINKERNAGEL RIVI: T cell-independent Type I antibody response against B cell epitopes expressed repetitively on recombinant virus particles. Proc. Natl. Acad. Sci. USA (1998) 95:9477–9481.
- KRATZ PA, BOTTCHER B, NASSAL M: Native display of complete foreign protein domains on the surface of hepatitis B virus capsids. Proc. Nati Acad. Sci. USA (1999) 96:1915–1920.
- SIEMASKO K, CLARK MR: The control and facilitation of MHC class II antigen processing by the BCR. Curr. Opin. hninunal. (2001) 13:32–36.
- YEWDELL JW, NORBURY CC, BENNINK JR: Mechanisms of exogenous antigen presentation by MHC class I molecules in vitro and in vivo: implications for generating CD8+ T cell responses to infectious agents, tumours, transplants, and vaccines. Adv. Innnunal. (1999) 73:1–77
- ZHOU J, GISSMANN L, ZENTGRAF H, MULLER H, PICKEN M, MULLER M: Early phase in the infection of cultured cells with papillomavirus virions. Virology(1995) 214:167–176.
- LENZ P, DAY PM, PANG YS etal.: Papillomavirus-like particles induce acute activation of dendritic cells. j Innnunal. (2001) 166:5346–5355.
- •Provides a mechanistic explanation for the high intrinsic immunogenicity of papffiomavirus VLPs.
- RUDOLF MP, FAUSCH SC, DA SILVA D, KAST WM: Human dendritic cells are activated by chimeric human papillomavirus Type 16 virus-like particles and induce epitope-specific human T cell responses in vitro. I Innnunal. (2001) 166:5917–5924.
- •Provides a mechanistic explanation for the high intrinsic immunogenicity of papillomavirus VLPs.
- GLENNIE MJ, JOHNSON PW: Clinical trials of antibody therapy. Innnunal. Today (2000) 21:403–410.
- HERTZ M, NEMAZEE D: Receptor editing and commitment in B-lymphocytes. Curr. Opin. Immune]. (1998) 10:208–213.
- CHEN X, KEARNEY JF: Generation and function of natural self-reactive B lymphocytes. &min. Innnunal. (1996) 8:19–27.
- DALUM I, JENSEN MR, HINDERSSON P, ELSNER HI, MOURITSEN S: Breaking of B cell tolerance toward a highly conserved self protein. j Innnunal. (1996) 157:4796–4804.
- FANG W, WEINTRAUB BC: et al: Self-reactive B lymphocytes overexpressing Bcl-XL escape negative selection and are tolerised by clonal anergy and receptor editing. Immunity (1998) 9:35–45.
- RATHMELL JC, FOURNIER S, WIENTRAUB BC, ALLISON JP, GOODNOW CC: Repression of B7.2 on self-reactive B cells is essential to prevent proliferation and allow Fas-mediated deletion by CD4+ T cells. j. Exp. Med. (1998) 188:651–659.
- ALBERT LJ, INMAN RD: Molecular mimicry and autoimmunity. N Erigl Med. (1999) 341:2068–2074.
- DALUM I, JENSEN MR, GREGORIUS K, THOMASEN CM, ELSNER HI, MOURITSEN S: Induction of cross-reactive antibodies against a self protein by immunisation with a modified self protein containing a foreign T helper epitope. Mol. Immunol. (1997) 34:1113–1120.
- TALWAR GP, SHARMA NC, DUBEY SK et al.: Isoimmunisation against human chorionic gonadotropin with conjugates of processed b-subunit of the hormone and tetanus toxoid. Proc. Nat. Acad. Sci. (1976) 73:218–222.
- DALUM I, BUTLER DM, JENSEN et al.: Therapeutic antibodies elicited by immunisation against TNF-alpha. Nature Biotechnol. (1999) 17:666–669.
- •Proof of concept demonstration that vaccine-induced antibodies to a central self-antigen can elicit a therapeutic response in mice.
- TALWAR GP, SINGH 0, PAL R et al.: A vaccine that prevents pregnancy in women. Proc. Natl. Acad. Sci. USA (1994) 91:8532–8536.
- •An interesting clinical trial of a first generation auto-antibody inducing vaccine.
- BACHMANN MF, ROHRER UH, KUNDIG TM, BURKI K, HENGARTNER H, ZINKERNAGEL RM: The influence of antigen organisation on B cell responsiveness. Science (1993) 262:1448–1451.
- CHACKERIAN B, LOWY DR, SCHILLER JT: Induction of autoantibodies to mouse CCR5 with recombinant papillomavirus particles. Proc. Natl. Acad. Li. USA (1999) 96:2373–2378.
- •The first demonstration that B-cell tolerance to a cell surface central antigen can be effectively broken by display of the target peptide on the surface of a VLP.
- SLOVIN SF, RAGUPATHI G, ADLURI et al.: Carbohydrate vaccines in cancer: immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man. Proc. Natl. Acad. Sci. USA (1999) 96:5710–5715.
- KUDRYASHOV V, GLUNZ PW, WILLIAMS LJ, HINTERMANN S, DANISHEFSKY SJ, LLOYD KO: Toward optimised carbohydrate-based anticancer vaccines: Epitope clustering, carrier structure, and adjuvant all influence antibody responses to Lewisy conjugates in mice. Proc. Nail. Acad. Sci. USA (2001) 98:3264–3269.
- DA SILVA D, VELDERS MP, RUDOLF MP SCHILLER JT, KAST WM: Papillomavirus virus-like particles as anticancer vaccines. Curr. Opin. Mol. Therapeutics (1999) 1:82–88.
Website
- www.hpv2000.com 18th International Papillomavirus Conference